PETVW — PetVivo Holdings, Inc.

Summary of PetVivo Holdings, Inc. (PETVW) Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Total revenue for Q2 2026 reached $303,000, a 51% increase year-over-year. For the first half of the fiscal year, revenues were up 85% to over $600,000.
• Gross Profit: Gross profit was $220,000, representing 72.6% of revenues, down from 89.5% in the same quarter last year due to the introduction of the new PrecisePRP product.
• Operating Expenses: Total operating expenses decreased by 3% to $2.3 million, contributing to a 5% reduction in operating loss to approximately $2 million.
• Net Loss: The net loss for the quarter was $3 million, or $0.11 per share, compared to a net loss of $2.2 million in the prior year. The increase in loss was attributed to higher interest expenses following the conversion of convertible notes.
• Cash Position: Available cash increased to $768,000 from $220,000 at the end of the previous fiscal year. Total liabilities decreased significantly to $1.1 million from $5.1 million.

2. Strategic Updates and Business Highlights

• Product Momentum: Continued growth in the adoption of Spryng with OsteoCushion technology and the new PrecisePRP product, which is now being marketed for both canine and equine applications.
• Market Expansion: Entry into international markets, including the U.K. and Mexico, with significant growth potential in the veterinary health care market.
• Sales Growth: U.S. distributor sales increased by 35%, contributing to 75% of total revenues. The company has expanded its sales force and marketing efforts.
• New Partnerships: Strategic collaborations with organizations like Veterinary Growth Partners and Commonwealth Markets to promote product adoption and clinical use.
• Technological Advancements: Introduction of an exclusive licensing agreement with Digital Landia for AI technology aimed at enhancing veterinary diagnostics and client engagement.

3. Forward Guidance and Outlook

• Growth Expectations: The company anticipates continued strong sales momentum through the remainder of fiscal 2026, with expectations for record growth and improved bottom lines.
• Market Potential: The U.S. animal health market is projected to double to $11.3 billion by 2030, providing significant growth opportunities.
• Upcoming Events: The third and fourth quarters are traditionally the strongest, with increased industry events expected to drive product awareness and new orders.

4. Bad News, Challenges, or Points of Concern

• Gross Margin Decline: The introduction of PrecisePRP has led to a decrease in gross margin, which may impact profitability in the short term.
• Net Loss Increase: Despite revenue growth, the net loss widened due to increased interest expenses, raising concerns about financial sustainability.
• Adoption Challenges: Slow adoption rates among veterinarians, particularly in the companion animal market, may hinder growth. The learning curve for new products is significant, and corporate adoption remains a challenge.
• Competitive Pressures: The veterinary market is competitive, and gaining widespread acceptance for new treatments can be time-consuming.

5. Notable Q&A Insights

• User Adoption: The CEO noted that heavy users of Spryng typically take 6 months to a year to fully adopt the product, indicating a slow but steady growth in usage.
• Revenue Breakdown: Approximately 58% of revenue came from Spryng and 42% from the canine version of PrecisePRP, with the equine version recently launched.
• Corporate Adoption: There is no widespread corporate adoption yet, as decisions are often made at the individual veterinarian level, which can slow the process of gaining market share.
• Future Reporting: The CFO indicated plans to provide more detailed segment reporting in the future, including breakdowns between companion and equine products.

This summary encapsulates the key points from the earnings call, highlighting both the positive developments and the challenges faced by PetVivo as it navigates growth in the veterinary market.